Lexeo Therapeutics Inc LXEO

Healthcare Biotechnology

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hype...

NDAQ:LXEO - Post by User

Lexeo Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

(216)
•••

Post by coolfooldumbguyon Jul 15, 2024 9:06pm

65 Views

Post# 36133945

Geriatric medical company

Working on old folks medical problems that includes me too,since I am a baby boomer,and a lot of my friends and my relatives too are being diagnosed with these conditions.

<< Previous

Bullboard Posts

Next >>

The USD 88 shock: Are UBS and Citigroup forcing the silver market to its knees, or are we witnessing the ultimate short squeeze? Opportunities at Silver North Resources